31° Partly Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Community Choice

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Ord Shs (OP:TKPHF)

29.35 +0.69 (+2.41%)

Streaming Delayed Price Updated: 2:04 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ord Shs

< Previous 1 2 Next >

Current Analysis: Takeda Pharmaceutical ↗

April 09, 2024

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. Over the past year, Takeda’s share price fell 20.5% from $34.04 to $27.05 as of...

Via Talk Markets

Current Analysis: Takeda Pharmaceuticals (TKPHF) ↗

November 12, 2023

TKPHF is the largest Japanese drug company. Furthermore the estimated $45.50 dividend income from $1k invested is about 1.64 times greater than Friday’s price of a single share

Via Talk Markets

Takeda Moves Out From Licensing Agreement With Theravance Biopharma ↗

May 11, 2023

In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'...

Via Benzinga

Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues ↗

May 11, 2023

Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its

Via Benzinga

United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review ↗

April 21, 2023

The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.

Via Benzinga

Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B ↗

December 13, 2022

Via Benzinga

Takeda's Dengue Vaccine Candidate Under FDA Priority Review ↗

November 23, 2022

Via Benzinga

Takeda Posts Lower 1H Profit, Lifts FY22 Outlook ↗

October 27, 2022

Via Benzinga

Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids ↗

October 05, 2022

Via Benzinga

Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says ↗

March 20, 2023

Via Benzinga

Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients ↗

February 21, 2023

Via Benzinga

Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged ↗

February 02, 2023

Via Benzinga

Why Shares of Phathom Pharmaceutical Jumped This Week ↗

January 28, 2023

Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.

Via The Motley Fool

Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study ↗

January 09, 2023

Via Benzinga

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing

December 06, 2022

From Singapore Economic Development Board (EDB)A*STAR

Via ACN Newswire

Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder ↗

July 21, 2022

Via Benzinga

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22 ↗

May 11, 2022

Via Benzinga

Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings ↗

November 17, 2022

Via Benzinga

With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report ↗

August 30, 2022

Via Benzinga

After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact ↗

August 26, 2022

Via Benzinga

EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets ↗

July 27, 2022

BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome...

Via Benzinga

Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years ↗

July 01, 2022

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.

Via Benzinga

FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder ↗

January 31, 2022

The

Via Benzinga

Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients ↗

April 22, 2022

Via Benzinga

Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection ↗

March 08, 2022

Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID...

Via Benzinga

Roche And AstraZeneca Settle Ultomiris Patent Lawsuit ↗

February 22, 2022

Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...

Via Benzinga

Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics ↗

February 22, 2022

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four...

Via Benzinga

Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months ↗

February 18, 2022

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of...

Via Benzinga

FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study ↗

December 22, 2021

Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral...

Via Benzinga

Novavax Files For Approval Of Its COVID-19 Vaccine In Japan ↗

December 16, 2021

Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Takeda Pharmaceutical Ord Shs (OP:TKPHF)

All News about Takeda Pharmaceutical Ord Shs

Sections

Services